10-Q: BioNexus Gene Lab Corp. Reports First Quarter 2024 Results

BioNexus Gene Lab Corp. reports a net loss of $103,757 for the first quarter of 2024, with a slight increase in revenue compared to the same period last year.

Summary

• BioNexus Gene Lab Corp. reported a net loss of $103,757 for the three months ended March 31, 2024, compared to a net loss of $69,066 for the same period in 2023.
• The company's revenue for the quarter was $2,381,851, a slight increase from $2,377,205 in the first quarter of 2023.
• Cost of revenue increased slightly to $2,016,820 from $2,008,308 year-over-year.
• Gross profit decreased slightly to $365,031 from $368,897 in the prior year.
• Operating expenses rose to $645,906 from $536,872, primarily due to increased general and administrative costs.
• The company experienced a foreign currency translation loss of $209,908, compared to a loss of $39,039 in the same period last year.
• Basic and diluted loss per share was $0.018, compared to $0.007 in the first quarter of 2023.
• The company's working capital was $6,188,903 as of March 31, 2024, compared to $6,415,877 as of December 31, 2023.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with a slight increase in revenue but a significant increase in net loss and operating expenses. The foreign currency loss and the need to regain Nasdaq compliance add to the negative sentiment. The company's RNA screening business is still being impacted by the pandemic, and the company's financial performance is concerning.

Positives

• The company's revenue saw a slight increase of 0.2% compared to the same quarter last year.
• Chemrex's revenue increased by 0.38% from the prior quarter.
• Other income increased by approximately 72% due to dividends received from investments, gain on fair value of investment, recovery of expected credit losses and gains on foreign exchange rates.

Negatives

• The company's net loss increased by approximately 56.1% compared to the same quarter last year.
• Operating expenses increased by 20.3% due to higher general and administrative costs.
• MRNA Scientific-Malaysia's revenue decreased by 57.4% due to RNA machine breakdowns.
• The company experienced a significant foreign currency translation loss of $209,908.
• Gross profit decreased by approximately 1% from the prior period.

Risks

• The company's RNA screening business is still being impacted by the lingering effects of the COVID-19 pandemic.
• Chemrex's customers are still experiencing supply chain issues and reduced demand due to the pandemic.
• The company's liquidity could be materially decreased by the addition of administrative and marketing personnel, website development, increased advertising and marketing, and the costs of being a public company.
• The company is exposed to fluctuations in foreign exchange rates.
• The company needs to regain compliance with Nasdaq's minimum bid price rule by November 4, 2024.

Future Outlook

The company believes that cash flow from operations will be sufficient to sustain its current level of operations for at least the next 12 months. The company is also focused on regaining compliance with Nasdaq's minimum bid price rule.

Management Comments

• Management believes that most people were reluctant to visit hospitals and clinics in view of the post Covid-19 Omicron and its subvariants for fear of transmission from other patients or medical staff.
• Management considers its internal control over financial reporting required further improvement.

Industry Context

The company's RNA screening business is still being impacted by the lingering effects of the COVID-19 pandemic, which has also affected the supply chains and demand for Chemrex's customers. The company is operating in a challenging environment with ongoing economic and health-related uncertainties.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without more specific information on the company's peers. However, the company's performance is impacted by the ongoing effects of the COVID-19 pandemic, which has affected many businesses in the healthcare and industrial sectors.
• The company's revenue is primarily driven by Chemrex, a wholesaler of industrial chemicals, which operates in a different market segment than the company's RNA screening business. This makes direct comparisons to other biotech companies difficult.
• The company's net loss and increased operating expenses are concerning, and it will be important to monitor the company's progress in improving its financial performance in future quarters.
• The company's need to regain compliance with Nasdaq's minimum bid price rule is a significant challenge that could impact its ability to raise capital and maintain its listing.

Stakeholder Impact

• Shareholders are negatively impacted by the increased net loss and the need to regain Nasdaq compliance.
• Employees may be impacted by the company's efforts to reduce operating expenses.
• Customers of Chemrex may be impacted by the ongoing supply chain issues and reduced demand.
• Suppliers may be impacted by the company's efforts to reduce costs.

Next Steps

• The company needs to focus on improving its financial performance and reducing its operating expenses.
• The company needs to regain compliance with Nasdaq's minimum bid price rule by November 4, 2024.
• The company needs to monitor the impact of the COVID-19 pandemic on its businesses and adapt its strategies accordingly.
• The company needs to evaluate the merits of the settlement offer from the supplier and its legal options to resolve the issue expeditiously.

Key Dates

Keywords

BioNexus Gene Lab Corp, BGLC, MRNA Scientific, Chemrex, financial results, quarterly report, RNA screening, industrial chemicals, net loss, revenue, operating expenses, foreign currency loss, Nasdaq, compliance